Source: Good News Network
The US Food and Drug Administration has just granted a “Breakthrough Therapy” designation to a treatment that uses psychedelic mushrooms as a therapy for treatment-resistant depression.
The FDA designates a drug as a Breakthrough Therapy if preliminary clinical evidence shows that it may demonstrate substantial improvement over available therapy.
Breakthrough Therapies are supported by the FDA throughout the clinical development program to ensure as efficient a process as possible.The treatment was developed by Compass Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health.
Dr. Robin Carhart-Harris, Head of the Psychedelic Research Group at the Imperial College London, said: “In our 2015 study, we provided psilocybin to 19 patients in a clinical setting, coupled with psychological support, and found promising signals of efficacy and safety as treatment for treatment-resistant depression.”
RELATED: FDA Approves Once-Monthly Preventative Migraine Treatment With No Major Side Effects
Treatment-resistant depression is a huge unmet need, affecting 100 million people around the world who do not respond to existing treatments. Depression is one of the fastest growing health problems we face today, and mental health disorders are the leading cause of ill-health and disability worldwide. The Breakthrough Therapy designation for psilocybin therapy highlights the importance of supporting early research that can be translated to clinically meaningful outcomes.
“The Breakthrough Therapy designation is a strong endorsement for the potential of psilocybin therapy.
We look forward to learning more as further clinical studies are carried out, by our team at Imperial College as well as in Compass’s multi-centre trial,” added Dr. Carhart-Harris.The…
The post FDA Grants ‘Breakthrough’ Status to Psilocybin Mushroom Therapy for Untreatable Depression appeared first on FeedBox.